Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 6/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.68 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.64 |
| ▸ | KDR | P35968 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7482948 | 0.91 | FGFR2 (0.61) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL7486400 | 0.86 | FGFR2 (0.84) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL7482941 | 0.84 | FGFR2 (0.62) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL7480589 | 0.84 | FGFR2 (0.73) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL12444104 | 0.83 | PDGFRA (0.76) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL4470477 | 0.82 | PDGFRA (0.74) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL16083535 | 0.82 | PDGFRA (0.74) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL167396 | 0.82 | PDGFRA (0.74) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL7484470 | 0.82 | PDGFRA (0.74) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL3893791 | 0.82 | PDGFRA (0.65) | PDGFRAPDGFRBFGFR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163877-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2020-05-28 | — | — | US | claimed |
| US-11458199-B2 | Liposome formulations | OPKO PHARMACEUTICALS, LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20160264969-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | OPHTHOTECH CORPORATION | 2016-09-15 | — | — | US | disclosed |
| US-8969344-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140179621-A1 | Methods for Treating or Preventing Ophthalmological Diseases | OPHTHOTECH CORPORATION (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130085152-A1 | Method For Assay On The Effect Of Vascularization Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-0860433-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BREWERY (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179621-A1 | Methods for Treating or Preventing Ophthalmological Diseases | VEGFA, PDGFA, PGF | PDGFRA 12/4885PDGFRB 14/4885FGFR2 416/4885 |
| US-20130085152-A1 | Method For Assay On The Effect Of Vascularization Inhibitor | VEGFA, EDF1, HDGF | PDGFRA 173/4885PDGFRB 93/4885FGFR2 273/4885 |
| US-20160264969-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | VEGFA, PDGFA, PGF | PDGFRA 12/4885PDGFRB 14/4885FGFR2 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.